Hanmi Pharmaceutical Decides on Treasury Share Disposal

Recently, Hanmi Pharmaceutical has decided to dispose of treasury shares as a reward for employee performance. Consequently, Hanmi Pharmaceutical will dispose of 10,402 common shares, amounting to approximately 4.06198 billion KRW. This disposal is intended to provide employees with productivity incentives and significant performance contribution bonuses, demonstrating the company's commitment to sharing its success with its employees.

Disposal Details

The price for the shares to be disposed of is set at 390,500 KRW per common share. The planned disposal period is from July 29, 2026, to August 28, 2026. The disposal method involves transferring the shares from the treasury stock account to the securities accounts of the designated recipients, with Shinhan Investment Corp. acting as the entrusted intermediary.

• Recipients: 644 RSA (Restricted Stock Awards), 18 RSU (Restricted Stock Units)
• Shares to be granted via RSA: 7,562 shares
• Shares to be granted via RSU: 2,840 shares

The decision date for this disposal was July 28, 2026, and it was made with the attendance of three outside directors at the board meeting. Prior to this disposal, the treasury stock balance was 130,777 shares. After disposing of 8,997 shares, the year-end balance will be reduced to 121,880 shares. The number of shares planned for disposal represents 0.08% of the total issued shares (12,810,991 shares), and the company stated that the dilution effect on share value is expected to be limited.

Financial Status and Stock Performance

Hanmi Pharmaceutical's consolidated financial status as of the fiscal year ended December 2025 is as follows:

• Total Assets: 2.1376 trillion KRW
• Total Liabilities: 714.7 billion KRW
• Total Equity: 1.4229 trillion KRW
• Revenue: 1.5475 trillion KRW
• Operating Profit: 257.8 billion KRW
• Net Profit: 187.1 billion KRW

Hanmi Pharmaceutical, a pharmaceutical manufacturer listed on the KOSPI market on July 30, 2010, saw its stock price at 374,500 KRW as of July 28, 2026. This represents a decrease of 16,000 KRW (−4.1%) compared to the previous day. Such stock price fluctuations can be influenced by various market factors.

In Conclusion

Hanmi Pharmaceutical's decision to dispose of treasury shares is driven by the significant objective of rewarding employee performance. This move is expected to contribute to the company's sustained growth and talent acquisition. It will be interesting to observe Hanmi Pharmaceutical's future endeavors.